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1. Introduction 
        Disseminated melanoma represents one of the most treatment-resistant of all human 
malignancies. Drug resistance is not only acquired following drug therapy, but may be 
also present in untreated lesions. Consequently, adjuvant therapy, immunotherapy or 
chemotherapy, provide only modest improvements in outcome. Among new cancer cases, 
melanoma is continuing to rise in incidence at a rate exceeding all other cancers [1-3].
 
Melanocyte-directed enzyme prodrug therapy (MDEPT) has been suggested as a 
possible selective strategy towards the treatment of malignant melanoma [4]. MDEPT 
offers a highly selective triggering mechanism for drug delivery because of the unique 
occurrence of tyrosinase enzyme expression in melanocytes and melanoma cells. When 
melanocytes become malignant, the genes expressing tyrosinase become up-regulated, 
resulting in a marked increase in the tyrosinase levels within the cancerous cells [5]. A 
number of tyrosinase-dependent prodrug strategies have been investigated for the 
treatment of melanoma, in which tyrosinase mediates the release of an anticancer agent 
from prodrugs via a cyclization-drug release mechanism [6]. Jordan and co-workers have 
synthesized several prodrugs 1 of nitrogen mustards as the cytotoxic agent connected via 
a carbamate, urea or thiourea group to the tyrosinase sensitive unit [4,7,8]. These 
prodrugs act as tyrosinase substrates and release the mustard drug after enzymatic 
oxidation [7-9].  
Dacarbazine (DTIC), 2, remains the single FDA-approved chemotherapeutic agent in 
common use for metastatic melanoma. Among all the chemotherapeutic agents tested 
against this malignancy, DTIC is the most active single agent and thus considered the 
reference drug [10, 11]. Related 1-aryl-3,3-dimethyltriazenes, 3, (see Scheme 1) are also 
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documented as anticancer drugs, but with reduced selectivity for tumour cells [12,13]. 
The biological action of DTIC and the dimethyltriazenes, 3, is a consequence of their 
capacity to alkylate DNA and RNA via the corresponding monomethyltriazene 4 
following metabolic oxidation by cytochrome P450 enzymes (Scheme 1) [12,14,15].  
Thus, improvements in the treatment of melanoma may be attained by the development 
of a prodrug strategy that can specifically deliver the ultimate methylating agent to 
malignant cells. Since monomethyltriazenes are as good leaving groups as alcohols [16], 
we envisaged that coupling them to tyrosinase substrates would identify suitable prodrugs 
5 capable of regenerating the alkylating metabolite 4 via the pathway depicted in Scheme 
2. We now report the synthesis of triazene derivatives 5a-f (Scheme 3), and their 
evaluation as substrates for tyrosinase.  
 
Text graphic 1 near here 
Scheme 1 near here 
Scheme 2 near here 
 
2. Results and Discussion 
 
2.1. Synthesis  
Initial attempts to synthesize compounds 5 involved the preparation of ethyl carbamates, 
6a, from the corresponding monomethyltriazenes 4, according to the published procedure 
(Scheme 3) [17]. However, carbamates 6a proved to be unreactive towards tyramine and 
dopamine in the presence of a wide range of bases. Consequently, we synthesized the 
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corresponding 4-nitrophenyl carbamate derivatives 6b and gratifyingly reaction of these 
with tyramine and dopamine in the presence of triethylamine gave the desired compounds 
5a-g in good yields. 
 
Scheme 3 near here 
 
2.2. Stability in Phosphate Buffer and Human Plasma 
        The hydrolysis of triazene derivatives, 5a-g, to the corresponding 1-aryl-3-
methyltriazenes, 4, was studied both in isotonic phosphate buffer (PBS, containing 20% 
of dimethylsulfoxide) and in 80% human plasma, at 37ºC. These reactions were followed 
by HPLC by monitoring both the loss of starting material and the formation of products. 
The kinetics of the hydrolysis of each prodrug in both media followed pseudo-first-order 
kinetics over four to five half-lives.   
Half-lives for the hydrolysis in PBS are presented in Table 1. Inspection of Table 
1 shows that these compounds are generally very stable in this medium; no measurable 
decomposition of the tyramine-based derivatives 5a-c over 15 days or of the dopamine 
derivative 5g over 2 days could be detected, while the tyramine derivative 5d (half-life 15 
days) and the dopamine derivatives 5e,f (half-lives 15h and 20h, respectively) hydrolyzed 
only very slowly. It seems, however, that the prodrugs containing dopamine are the more 
reactive.   
We were interested in examining the stability of the prodrugs in human plasma because it 
contains a range of enzymes that could potentially catalyze the hydrolysis of such urea 
derivatives.  The dopamine-based triazene derivatives 5e-g are hydrolyzed to the 
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corresponding 1-aryl-3-methyltriazene 4 with half-lives ranging from 6h to 15h, implying 
that they are hydrolyzed in human plasma only ca. 1.5 times faster than in pH 7.4 buffer. 
In contrast, the tyramine-based derivatives 5a,c,d are stable in human plasma for 2d, 
while 5b is hydrolyzed with a half-life of 71h. These results indicate that tyramine 
substrates are less prone to plasma hydrolysis when compared with their dopamine 
counterparts.  
 
Table 1 near here 
 
2.3. Triazene derivatives as a substrate for tyrosinase 
The ability of triazene derivatives 5 to act as substrates of tyrosinase was studied by 
HPLC by determining the half-lives for activation for each compound in the presence of 
the enzyme (Table 1). HPLC analysis of reaction mixtures showed that both tyramine-, 
5a-d, and dopamine-derivatives, 5e-g, are rapidly consumed with half-lives ranging from 
6 to 18 min, thus indicating that they are excellent tyrosinase substrates. These triazene 
prodrugs have shorter half-lives in the presence of tyrosinase than the urea linked N-
mustard prodrugs described by Knaggs et al. [9]. For compound 5c Km = 0.31±0.08 mM 
and Vmax= 0.030±0.005 mM/min, and for compound 5f Km= 0.71±0.4 mM and Vmax 
0.31±0.14  mM/min. These Km values compare favourably with those reported for 
tyramine (0.51 mM) and dopamine (2.2 mM). The Vmax values correspond to turnover 
numbers of 0.6 s-1 and 6 s-1 for 5c and 5f, respectively, which are rather smaller than the 
25.9 s
-1
 and 439 s
-1
 observed for tyramine and dopamine substrates [18], though the 
relative sizes between the tyramine and dopamine derivatives are similar.  This 
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observation is consistent with the report that tyrosinase accepts mono-, di- and 
trihydroxyphenols as substrates but displays the highest turnover rates for 
dihydroxyphenols [19, 20].
 
The rates of decomposition of tyramine derivatives 5e-g are 
not significantly affected by the substituents in the triazene moiety, presumably reflecting 
the significant distance between these substituents and the catechol moiety. Interestingly, 
although the half lifes of the tyramine derivatives 5a-d are little affected by the 
substituent in the triazene moiety also, there is a correlation between log t1/2 values and 
the Hammett σp values yielding a ρ value of -0.2 (r
2
 = 0.99, Figure 1). The origin of this 
rather small effect is not clear.  
         
 
Figure 1 near here 
 
Inspection of the HPLC traces of the reaction mixtures of the tyrosinase catalysed 
reactions revealed that triazenes 5 were rapidily converted to a metabolite that did not 
correspond either to the appropriate monomethyltriazene 4 or its aniline decomposition 
product [12]. To gain some insight to the structure of this metabolite, an LC-MS study of 
the reaction mixtures was performed.  It was not possible to obtain efficient ionization of 
the substrates or products by electrospray ionization (positive or negative modes) using 
the chromatographic conditions used for kinetic experiments. However, using the APCI 
source we were able to detect formic acid adducts of the substrates 5 and their 
corresponding metabolites; in some cases we could also detect the molecular ions (Table 
2). For this reason ammonium formate was added to the aqueous eluent. To achieve 
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adequate HPLC separations, we also required the pH of the eluent to be kept low; 
therefore the aqueous reaction solutions were acidified to pH 3.5 using formic acid. 
We were able to identify the main HPLC peak formed through activation of 
triazenes 5b,c and e by tyrosinase. In the case of the tyramine derivatives, 5b,c, the mass 
of the metabolite was 14 units higher than the mass of the substrate (as exemplified for 5c 
in Figure 2). This mass difference can be ascribed to the conversion of 5b, and 5c to the 
corresponding ortho-quinone 7 (Scheme 2). In the case of the dopamine derivative, 5e, 
chromatographic separation proved more difficult since the product peak overlapped with 
the substrate, as expected for a quinone product with similar structure and polarity to the 
substrate. Separation proved possible, however, using a gradient program and lower 
formate concentration. Formation of the ortho-quinone 7 corresponding to 5e was 
confirmed by LC-MS since the metabolite peak, which eluted 0.5 min earlier than the 
substrate, gave a formic acid adduct ion of 2 mass units less than the substrate (Table 2). 
Overall, these results indicate that although the prodrugs are substrates for tyrosinase, the 
release of the cytotoxic monomethyltriazene 4 does not occur under the conditions used. 
This suggests that subsequent cyclization activation of the ortho-quinone 7 (Scheme 2) is 
not an efficient process. Our results are consistent with recent studies that show that in 
urea or carbamate derivatives of dopamine the nitrogen atom is not sufficiently 
nucleophilic to effect the necessary cyclization that results in release of the antitumour 
agent [21, 22].   
 
Table 2 near here 
Figure 2 near here 
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3. Conclusions 
        In conclusion, the synthesis and analysis of a range of prodrugs derived from 
tyramine and dopamine, of potential use within MDEPT, has been evaluated. These 
compounds display excellent stability both in pH 7.4 buffer and in human plasma and 
simultaneously are good substrates for tyrosinase. The tyrosinase-catalysed reaction is 
very efficient in liberating an oxidized metabolite, but our HPLC and LC-MS data 
demonstrate that release of a cytotoxic monomethyltriazene does not occur for the urea-
linked derivatives 5. The present work demonstrates that drug release, which requires an 
activation process involving an intramolecular Michael addition reaction, requires a much 
better nucleophile than the urea nitrogen atom. Future work will therefore focus on the 
design of derivatives that have improved cyclization capacity while retaining excellent 
stability in aqueous solution. Such an approach shall also take account of the fact that 
dopamine derivatives are more rapidly metabolized by tyrosinase. 
 
 
4. Experimental  
 
4.1. General information 
Melting points were determined using a Kofler camera Bock Monoscop M and are 
uncorrected. Elemental analyses were performed by Instituto Tecnológico e Nuclear, 
Portugal. FTIR spectra were recorded as KBr discs using a Nicolet Impact 400 
spectrophotometer. 
1
H- and 
13
C-NMR spectra were obtained in CDCl3 or DMSO 
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solutions using a Bruker AM 400 WB. Coupling constants, J, are expressed in Hz. 
Chemicals were purchased from Sigma- Aldrich Chemical Company (U.K.) and B.D.H. 
Merck Chemical Company (U.K.). All chemicals and solvents were of reagent grade, 
except buffers substances and HPLC solvents, which were analytical grade and 
LiChrosolv

 grade, respectively. Column chromatography was performed using silica gel 
60 mesh 70-230 (Merck). 
 
4.2. Synthesis 
General procedures for the synthesis of prodrugs 5a-g. A dichloromethane solution (5 
mL) containing the appropriate monomethyltriazene (1.31 mmol) was added to a solution 
of 4-nitrophenyl chloroformate (1.58 mmol) and pyridine (1.31 mmol, 106 µL). After 
stirring for 24 h at room temperature, the reaction mixture was filtered and concentrated 
in vacuo. The crude product so-obtained was purified by column chromatography and 
used immediately. The pure carbamate (0.425 mmol) was dissolved in THF (10 mL) and 
tyramine (or dopamine) (0.863 mmol) and triethylamine (1.3 mmol, 180 µL) were added. 
After 48 h at room temperature, the solution was concentrated in vacuo and the crude 
product purified by column chromatography (ethylic ether: petroleum ether, 7:3).  
 
3-[2-(4-Hydroxyphenyl)ethylaminocarbonyl]-3-methyl-1-(4-acetylphenyl)triazene 
(5a). Yield 50%; m.p. 178-180 ºC; νmax/cm
-1
 3409, 3362, 1748, 1672; 
1
H NMR (CDCl3): 
δ 2.67 (3H, s, CH3CO), 2.87 (2H, t, J = 8.0 Hz, CH2Ar), 3.48 (3H, s, NCH3), 3.67 (2H, q, 
J = 8.0 Hz, NHCH2CH2), 5.47 (1H, s, OH), 6.85-7.13 (4H, AA'BB', J = 8.0 Hz, OHAr), 
7.44-8.03 (4H, AA'BB', J = 8.0 Hz, COAr); 13C  NMR (100 MHz, CDCl3): δ 27.29 
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(CH3CO), 29.18 (NCH3), 35.21 (CH2Ar), 42.56 (NCH2), 115.66-136.41 (CAr), 152.37 
(CNN), 154.16 (COH), 156.18 (CO), 197.67 (CH3CO). Anal. Calcd for C18H20N4O3:  C, 
63.5; H, 5.9; N, 16.5. Found: C, 63.5; H, 5.9; N, 16.4..  
 
3-[2-(4-Hydroxyphenyl)ethylaminocarbonyl]-3-methyl-1-(4-
ethoxycarbonylphenyl)triazene (5b). Yield 68%; m.p. 158-160 ºC; νmax /cm
-1
 3415, 
3280, 2962, 1708, 1676; 1H NMR (CDCl3): δ 1.42 (3H, t, J = 7.0 Hz, CH3CH2), 2.84 
(2H, t, J = 6.8 Hz, CH2Ar), 3.46 (3H, s, NCH3), 3.65 (2H, q, J = 6.4 Hz, NHCH2CH2Ar), 
4.40 (2H, q, J = 7.0 Hz, CH3CH2), 6.14 (1H, s, OH), 6.52 (1H, br t, J = 5.2 Hz, NH), 
6.85-7.10 (4H, AA'BB', J = 8.4 Hz, HOAr), 7.41-8.09 (4H, AA'BB', J = 8.8 Hz, NArCO); 
13C  NMR (100 MHz, CDCl3): δ 14.33 (CH3CH2), 28.61 (NCH3), 34.98 (CH2Ar), 41.68 
(NCH2), 61.33 (CH3CH2), 115.69-130.65 (CAr), 152.36 (CNN), 154.36 (COH), 154.87 
(CO), 166.48 (COCH2CH3). Anal. Calcd for C19H22N4O4: C, 61.6; H, 6.0; N, 15.1. 
Found: C, 61.5; H, 5.8; N, 14.9..  
3-[2-(4-Hydroxyphenyl)ethylaminocarbonyl]-3-methyl-1-(4-cyanophenyl)triazene 
(5c). Yield 55%; m.p. 156-158 ºC; νmax /cm
-1 3221, 3411, 3018, 2966, 2224, 1678, 1613; 
1
H NMR (CDCl3): δ 2.83 (2H, t, J = 6.8 Hz, CH2Ar), 3.45 (3H, s, NCH3), 3.59-3.36 (2H, 
q, J = 4.0 Hz, CH2CH2Ar), 6.56 (1H, br t, NHCH2), 6.72 (1H, s, ArOH), 6.79-7.08 (4H, 
AA'BB', J = 4.8 Hz, ArH), 7.47-7.74 (4H, AA'BB', J = 8.4 Hz, ArH); 13C NMR (100 
MHz, CDCl3): δ 27.38 (NCH3), 33.49 (CH2Ar), 40.29 (CH2CH2Ar), 109.80 (CCN), 
114.24-117.46 (CAr), 121.14 (CN), 128.46 (CAr), 131.94 (CAr), 150.73 (CNN); 152.61 
(COH); 154.13 (CO). Anal. Calcd for C17H17N5O2: C, 63.2; H, 5.3; N, 21.7. Found: C, 
63.2; H, 5.5; N, 21.6.  
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3-[2-(4-Hydroxyphenyl)ethylaminocarbonyl]-3-methyl-1-(4-tolyl)triazene (5d). Yield 
53%; m.p. 196-197 ºC; νmax /cm
-1 3363, 3027, 2923, 1678; 1H NMR (CDCl3): δ 2.41 (3H, 
s, CH3Ar), 2.85 (2H, t, J = 6.8 Hz, CH2Ar), 3.45 (3H, s, NCH3), 3.64 (2H, q, J = 6.2 Hz, 
CH2CH2Ar), 5.64 (1H, s, OH), 6.55 (1H, br t, NH), 6.85-7.12 (4H, AA'BB', J = 7.6 Hz, 
ArMe), 7.24-7.34 (4H, AA'BB', J = 7.8 Hz, ArCN); 
13
C NMR (100 MHz, CDCl3): δ 
21.23 (CH3Ar), 28.65 (NCH3), 35.30 (CH2Ar), 42.46 (NCH2), 115.66-138.39 (CAr), 
146.91 (CNN), 154.54 (COH), 156.17 (CO). Anal. C17H20N4O2: C, 65.4; H, 6.5; N, 17.9. 
Found: C, 65.3; H, 6.3; N, 17.7.  
 
3-[2-(3,4-Dihydroxyphenyl)ethylaminocarbonyl]-3-methyl-1-(4-
acetylphenyl)triazene (5e). Yield 45%; m.p. 158-160 ºC; νmax /cm
-1 3560, 3500, 3400, 
1720, 1650; 
1
H NMR (DMSO-d6): δ 2.65 (3H, s, CH3CO), 2.77 (2H, t, J = 7.2 Hz, 
CH2Ar), 3.45 (3H, s, NCH3), 3.56 (2H, t, J = 7 Hz, NHCH2), 6.58-6.74 (3H, m, Ar), 7.65-
8.09 (4H, AA'BB', J = 7.0 Hz, ArAc); 
13
C NMR (100 MHz, DMSO-d6): δ 27.29 (CH3), 
29.18 (NCH3), 35.49 (CH2Ar), 42.61 (NCH2), 116.02-136.41 (CAr), 144.09 (COH), 
145.64 (COH), 152.37 (CNN), 154.14 (CO), 197.68(CO). Anal. Calcd for C18H20N4O4 : 
C, 60.7; H, 5.7; N, 15.7. Found: C, 60.5; H, 5.3; N, 15.6.  
 
3-[2-(3,4-Dihydroxyphenyl)ethylaminocarbonyl]-3-methyl-1-(4-
ethoxycarbonylphenyl)triazene  (5f). Yield 56%; m.p. 173-174ºC; νmax /cm
-1
 3410, 
1708, 1602; 1H NMR (DMSO-d6): δ 1.35 (3H, t, J =  7.2 Hz, CH3CH2O), 2.66 (2H, t, J =  
8.0 Hz, CH2Ar), 3.35 (5H, br s, NCH3 and NCH2), 4.34 (2H, q, J = 7.2 Hz, OCH2), 6.48-
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6,65 (3H, m, Ar), 7.82-8.04 (4H, AA'BB', J = 8.0 Hz, ArCO2Et), 7.91 (1H, br t , J = 8.0 
Hz, NH), 8.70 (1H, s, OH), 8.81 (1H, s, OH). 13C NMR (100 MHz, DMSO-d6): δ 14.65 
(CH3), 29.18 (NCH3), 35.50 (CH2Ar), 42.64 (NCH2), 61.33 (OCH2), 116.01-130.69 
(CAr), 144.09 (COH), 145.63 (COH), 152.48 (CNN), 154.12 (CO), 165.76 (CO). Anal. 
Calcd for C17H20N4O3: C, 62.2; H, 6.1; N, 15.2. Found: C, 62.2; H, 5.9; N, 15.1.  
 
3-[2-(3,4-Dihydroxyphenyl)ethylaminocarbonyl]-3-methyl-1-(4-tolyl)triazene (5g). 
Yield 26%; m.p. 151-153ºC; νmax /cm
-1
 3500, 3317, 3408, 1683. 
1
H NMR (DMSO-d6): δ 
2.35 (3H, s, CH3Ar), 2.65 (2H, t, J = 8.0 Hz, NCH2CH2Ar), 3.32 (3H, s, NCH3), 3.37 
(2H, m, NCH2CH2Ar), 6.48-6.67 (3H, m, Ar), 7.28-7.61 (4H, AA'BB', J = 8.0 Hz, Ar-
triazene), 7.73 (1H, br t, J = 5.6 Hz, NH), 8.71 (1H, OH), 8.82 (1H, OH). 
13
C NMR (100 
MHz, DMSO-d6): δ 21.25 (CH3), 28.66 (NCH3), 35.59 (CH2Ar), 42.49 (NCH2), 116.01-
138.39 (CAr), 144.07 (COH), 145.64 (COH), 146.90 (CNN), 154.51 (CO). Anal. Calcd 
for C17H20N4O3 : C, 62.2; H, 6.1; N, 17.1. Found: C, 62.5; H, 6.0; N, 17.1.   
 
4.3. HPLC analysis 
The analytical high-performance liquid chromatography (HPLC) system comprised a 
Merck Hitachi L-7110 pump with a L-7400 UV detector, a manual sample injection 
module equipped with a 20 µL loop, a Merck Lichrospher® 100 RP18 125 mm x 4.6 mm 
(5µm) column equipped with a Merck Lichrocart pre-column (Merck, Germany). For 
compounds 5a-d an acetonitrile/water (45:55) isocratic solvent system was used. For 
compounds 5e-g a gradient elution beginning with a mobile phase
 
of 95% water/5% 
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acetonitrile ramping
 
to 95% acetonitrile/5% water over 30 min was used. The column 
effluent was monitored at 300 nm for all compounds (5a-g). 
 
4.4. Apparent partition coefficients 
The apparent partition coefficients (log Pexp) were determined at room temperature using 
1-octanol-pH 7.4 phosphate buffer. Each phase was mutually saturated before the 
experiment. The volumes of each phase were chosen so that solute concentrations in the 
aqueous phase after distribution were readily measurable. The compounds were dissolved 
in 1-octanol and the 1-octanol-phosphate buffer mixtures were shaken for 30 min to reach 
an equilibrium distribution. Each phase was analyzed separately by HPLC, but the 
organic phase was diluted in acetonitrile (1:10) before HPLC analysis. Partition 
coefficients, Pexp, were calculated from the ratio of the peak area in octanol to the peak 
area in buffer.  
 
4.5. Hydrolysis in Buffer Solution 
Reaction mixtures were analyzed using HPLC. Usually, a 10 µL aliquot of a 10
-2
 M stock 
solution of prodrug 5 in acetonitrile was added to 10 mL of the appropriate thermostatted 
buffer solution (8 mL PBS and 2 mL DMSO). At regular intervals, samples of the 
reaction mixture were analyzed by HPLC using the following conditions: mobile phase, 
acetonitrile/water (the composition of which depended on the compound); flow rate 1.0 
mL/min. 
 
4.6. Hydrolysis in Human Plasma 
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Human plasma was obtained from the pooled, heparinised blood of healthy donors, and 
was frozen and stored at –70 ºC prior to use. For the hydrolysis experiments, the 
substrates were incubated at 37 ºC in human plasma that had been diluted to 80% (v/v) 
with pH 7.4 isotonic phosphate buffer. At appropriate intervals, aliquots of 200 µL were 
added to 400 µL of acetonitrile to both quench the reaction and precipitate plasma 
proteins. These samples were centrifuged and the supernatant analyzed by HPLC for the 
presence of substrate and products. 
 
4.7. Tyrosinase degradation studies. Mushroom tyrosinase (Sigma) was used at a 
concentration of 100U/mL in a solution comprising phosphate buffer (pH 7.4, 2.4 mL) 
and DMSO (0.6 mL) at 37ºC. A solution of the prodrug under investigation (15 µL of 10
-
2 M solution) was added and the mixture incubated with gentle stirring at 37ºC.  Aliquots 
were collected at selected time intervals and quenched by addition of an organic solvent 
(acetonitrile). The disappearance of the prodrug, with concomitant appearance of 
metabolites, was followed by HPLC for evaluation of the hydrolysis kinetics. 
 
 4.8. LC-MS Assays 
Analysis was performed on a Surveyor HPLC from Thermo Finnegan, San Jose C.A., 
USA equipped with an autosampler and a diode array detector. The mass spectrometry 
system was an LCQ ion trap mass spectrometer also from Thermo Finnegan, equipped 
with an APCI source. The LC-MS system was controlled by Excalibur version 1.3 
software (Thermo Finnegan – Surveyor, San Jose, USA). The analytical column was a 
Lichrospher RP-8 (125 × 4 mm, 5 µm) from Merck with a guard column of the same 
material. Separations were carried out with a flow rate of 0.7 mL/min at 50º C. Injections 
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were made with 20-100 µL of the 10
-4
 to 10
-5
 M solutions of the substrates in acetonitrile 
or the corresponding solutions after enzymatic reaction.  
In the case of the tyrosine derivatives, an isocratic system comprising 45% ammonium 
formate (p.a. Fluka, 20 mM, pH 3.5 with formic acid), 45% acetonitrile (LC-MS grade, 
Reidel-de Haën) and 10% methanol (LC-MS grade, Reidel-de Haën) was used. For the 
dopamine derivatives, separation was carried out using a gradient program, starting with 
95% ammonium formate (2 mM, pH 3.5)/5% acetonitrile for seven minutes ramping to 
35% acetonitrile over the next ten minutes. Detection by UV absorption was in the range 
200-400 nm.  
The following conditions were used for the APCI source in negative mode: vaporizer 
temperature, 400ºC; discharge current, 5 µA; temperature of the heated capillary 150ºC. 
Nitrogen was used as sheath gas and auxiliary gas with a gas flow rate of 80 and 40 
arbitrary units, respectively. The flow was diverted from the mass detector in the first 2 
minutes of each run.  
LC-MS was performed in total ion content mode (TIC) from m/z 50 to 1000.  
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Figure and Schemes Captions 
 
Figure 1. Hammett plot of the half-lives for the decomposition of tyramine-based 
triazenes 5a-d against σp values for the triazene substituents. 
 
Figure 2. TIC (A) and DAD (B) chromatograms of a solution of triazene 5c after 
enzymatic reaction with tyrosinase; the substrate is detected at 6.8 min and the product at 
5.3 min. Mass spectra for the product (C) and the triazene substrate (D) peaks. 
 
Scheme1. Metabolic pathway for dimethyltriazenes. 
Scheme 2. Activation pathway for tyramine-based triazene prodrugs triggered by 
tyrosinase.  
 
Scheme 3. Synthesis of triazene prodrugs 5. (i) ethyl or 4-nitrophenyl chloroformate, 
pyridine, CH2Cl2; (ii) 9b, tyramine or dopamine, triethylamine, THF.  
X = Me, Ac, CO2Et, CN; Y = H, OH 
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Table 1. Triazene prodrug 5 half-lives, t½,  in both PBS buffer (20% DMSO) and 80% 
human plasma at 37 ºC, their Log P values, and their ability to act as tyrosinase substrates 
(100 U/mL) 
 
 
 
 
OH
N
H
Y
N
O
N
N
X
CH
3
5  
 
 
 
 
Log Pexp 
 
 
 
 
t1/2  
Compound X Y  pH 7.4 
buffer (h)
a
 
80% human 
plasma (h)
a
 
Tyrosinase 
(min)
b
 
5a  Ac H 3.25± 0.07 c) d) 13.0 
5b CO2Et H 3.96± 0.09 c) 71.5 12.9 
5c CN H 2.89± 0.06 c) d) 11.8 
5d Me H 3.90± 0.06 364  d) 18.2 
5e  Ac OH 3.24± 0.13 15.1 9.30 9.9 
5f CO2Et OH 3.78± 0.09 20.8 14.7 6.1 
5g Me OH 4.17± 0.03 d) 5.66 8.4 
a) substrate concentration 10
-5
 M  b) substrate concentration  5 x 10
-5
 M 
c) stable for 15 days  d) stable for 2 days 
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Table 2. APCI MS of the triazene substrates 5b,c,e and their corresponding metabolites 
produced by tyrosinase activation. 
Compound 5b 5c 5e 
Substrate 
molecular ion 
 
415.7** 
322.7* 
368.4** 
355.0* 
400.6** 
Metabolite 
molecular ion 
383.6* 
429.3** 
336.6* 
382.2** 
 
398.6** 
* molecular ion; ** formic acid adduct  
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Figure 1 
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Figure 2 
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Scheme 1 
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Scheme 2 
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Scheme 3 
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X
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Y
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5a X = CH3CO Y = H
5b X = CO2Et  Y = H
5c X = CN  Y = H
5d X = Me  Y = H
5e X = CH3CO Y = OH
5f X = CO2Et  Y = OH
5g X = Me  Y = OH
(i)
(ii)
4 6a, R = Et
6b, R = 4-C6H4NO2 
Reagents: (i) EtOCOCl (for 6a) or 4-O2NC6H4OCOCl (for 6b)/pyridine/CH2Cl2 
(ii) tyramine (Y=H) or dopamine (Y=OH), Et3N, THF  
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Text graphic 1 
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